Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

10

11

12

13

14

15

16

17

18

19

20

21

22

23

>

>|

Found 115 Matches

Cidofovir_V12R1_FDA_20150709
Model Files Publication
Table 1 of main text, further discussion in supplemental file. Clarification: the value of intrinsic CL for hepatic elimination (0.41) is for undefined human liver microsomes according to retrograde calculation, with a unit of uL/min/mg. The operating hepatic CLint is driven by S9, which has a value of 0.13, obtained from sensitivity analysis to match HLM value above. This clarification will be informed to the journal.
Search Score: 1
Esomeprazole_V14R1_USFDA_20160711
Model Files Publication
Note: This compound file is for esomeprazole solution, not for delayed release esomeprazole formulations 2. V12R1 compound file built to simulate adult PK. Supplied file is a V14R1 file that has been tested to generate identical results under the condition of mutual interaction with R-omeprazole (Condition 2 in Table II in our publication).
Search Score: 1
Tramadol_V14R1_JohnsonandJohnson_20151029
Model Files Publication
V12 R1 compound file built to simulate adult Human PK and pediatric PK. Supplied file is for V14 R1. “Physiology-Based IVIVE Predictions of Tramadol from in Vitro Metabolism Data” in Pharm Res January 2015, Volume 32, Issue 1, pp 260-274 http://link.springer.com/article/10.1007%2Fs11095-014-1460-x “Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.” in AAPSJ November 2015, Volume 17, Issue 6, pp 1376-1387 http://link.springer.com/article/10.1208%2Fs12248-015-9803-z
Search Score: 1
DEAQ
Model Files Publication

Brand Name(s) include: N/A

Disease: Malaria

Drug Class: Antimalarials

Date Updated: June 2021

Related Files: Amodiaquine (parent drug)

The model at-a-glance

  Absorption Model
  • N/A

  Volume of Distribution

  • Minimal PBPK (Method 2)

  Route of Elimination
  • CLPO (non-specific) and renal clearance

  Perpetrator DDI
  • CYP2D6

  Validation

  • Simulations based on 1 clinical study describing multiple dose exposure of DHEA and 1 DDI study where formation of DHEA was the victim of a CYP2C9 mediated DDI were both within 1.5-fold of the observed values.

  Limitations
  • Clinical data has not been used to verify DEAQ as a perpetrator of CYP2D6-mediated DDIs

  Updates in V19
  • Updated DEAQ Ki for CYP2D6

 

Search Score: 1

|<

<

10

11

12

13

14

15

16

17

18

19

20

21

22

23

>

>|